APOLLOMICS INC
APLMNASDAQTrading Snapshot
- Day Range
- $23.85 – $24.38
- 52-Week Range
- $10.01 – $42.12
- Volume
- $2.66B
- Avg Volume
- $1.96B
- Shares Outstanding
- 2.2M
- Next Earnings
- Nov 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $9M
- Last Q Revenue
- $2M
- P/E Ratio
- -3.0
- P/S Ratio
- 5.8x
- EPS (TTM)
- $-25.98
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −61.8%
Why Investors Own APLM
- ✓High-growth profile — revenue up -9.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
APOLLOMICS INC
APLM
StockOtter · stockotter.spaceAbout APOLLOMICS INC
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Apollomics Announces $10 Million Private Placement Transaction
FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to addr
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to addr